Skip to content
High Tech Series B Founded 2002

Nanospectra

Developer of nanoparticle-based cancer treatment for solid tumors. The company is commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors such as Prostrate, Brain, or Breast cancers. The company provides AuroLase Therapy, a medical device for the ablation of various solid tumors. The company was founded in 2002 and headquartered in Houston, United States. It has…

📍 Houston, United States · Nanotechnology,

Funding snapshot

Last roundSeries B
Amount$6M
Date15 March 2023
Total raised$25M
Team size5

About

Developer of nanoparticle-based cancer treatment for solid tumors. The company is commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors such as Prostrate, Brain, or Breast cancers. The company provides AuroLase Therapy, a medical device for the ablation of various solid tumors. The company was founded in 2002 and headquartered in Houston, United States. It has raised $24.5M in series b funding, with backing from NIA, National Cancer Institute, Sirtex Medical, HHS, and others. The company operates in the High Tech - Nanotechnology, Life Sciences - Oncology, Life Sciences - Drug Delivery space. Its offerings span Oncology - Medical Devices - Therapies - Radiation Therapy and Drug Delivery - Nanoparticle Based.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Encapsulation,

Oncology > Medical Devices > Therapies > Radiation Therapy,

Drug Delivery > Nanoparticle Based

Institutional investors

NIA National Cancer Institute Sirtex Medical HHS Houston Angel Network

Latest coverage

No articles yet.

Raising like Nanospectra?

Analyze your pitch deck before your next raise.

Analyze My Deck →